896 results on '"Lotan, Tamara L"'
Search Results
102. Data from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
103. Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
104. Supplemental Table 1 from Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer
105. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma
106. Supplementary Figure 2 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
107. Supplementary Figure S5 from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
108. Supplementary Figure S4 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
109. Data from PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
110. Supplementary Table S2 from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
111. Table S6 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
112. 'Supp Fig S1' from Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer
113. Supplementary tables from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
114. Supplementary Table 1 from PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
115. Supp Tables from MSH2 Loss in Primary Prostate Cancer
116. Supp Fig S2 from MSH2 Loss in Primary Prostate Cancer
117. Supplementary Figure 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
118. supplemental legend from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
119. Data from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
120. Supplementary figures from Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
121. supp Tables from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
122. Supplementary Table S1 from Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer
123. supplemental figure legend and Materials and Methods from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
124. Supplementary Table 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
125. Sup Fig 1 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
126. Supplementary Data from Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer
127. Sup Fig 2 from Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
128. Supplementary Data from CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
129. Supplementary Movie 2B from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
130. Supplementary Figure 2 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
131. Supplementary Figure 5 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
132. Supplementary Figure 3 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
133. Supplementary Figure 1 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
134. Supplementary Movie 1 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
135. Supplementary Figure 4 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
136. Supplementary Figure 6 from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
137. Data from mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss
138. Reprint of: de novo neuroendocrine features in prostate cancer
139. Impact of concurrent tumor events on the prostate cancer outcomes of germline BRCA2 mutation carriers
140. TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.
141. Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
142. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.
143. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer
144. ERG Status at the Margin is Associated with Biochemical Recurrence after Radical Prostatectomy with Positive Surgical Margins
145. Overlap of CD44 expression between prostatic small cell carcinoma and acinar adenocarcinoma
146. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas
147. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
148. mTORCI loss impairs epidermal adhesion via TGF-[beta]/Rho kinase activation
149. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
150. Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.